New TomTec rises from ashes
TomTec's 3-D ultrasound technology lives on. The defunct ultrasound developer has sold rights to the technology to a group of managers from the company's German subsidiary in Munich. The executives have formed a new company, TomTec GmbH, with the
TomTec's 3-D ultrasound technology lives on. The defunct ultrasound developer has sold rights to the technology to a group of managers from the company's German subsidiary in Munich. The executives have formed a new company, TomTec GmbH, with the intention of carrying forward TomTec's 3-D legacy.
TomTec Imaging Systems closed its doors last month after its venture-capital backers pulled out of the company and its management failed to find new funding (SCAN 6/11/97). In liquidating the company, TomTec's management said it intended to sell off the company's assets.
The Munich-based management team includes Bernhard Mumm, Frank Schlau, and Ulrich Haupt, who intend to resume on a worldwide basis all of the 3-D business activities and end-user relationships of TomTec Imaging Systems. The Munich facility had been the headquarters of TomTec predecessor Tomographic Technologies, which was merged with Prism Imaging/Freeland Systems to create TomTec Imaging Systems in late 1993.
All of TomTec's 3-D products, including TomTec Echo-Scan, EchoView, and Compact 3-D, will continue to be produced and marketed. TomTec GmbH will also continue the development of Windows NT-based clinical procedure and visualization packages for cardiac and general imaging applications.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
